Adverse Drug Reactions of Antihypertensive Drugs: a Review Sandhoshini Meena S 1, Praveen D 2, Ranadheer Chowdary P 2, M
Total Page:16
File Type:pdf, Size:1020Kb
High Technology Letters ISSN NO : 1006-6748 Adverse Drug Reactions of Antihypertensive Drugs: A Review Sandhoshini Meena S 1, Praveen D 2, Ranadheer Chowdary P 2, M. Vijey Aanandhi 3* 1School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai, India. 2Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai, India. 3Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai, India. Corresponding Author Dr. M. Vijey Aanandhi Professor and Head, Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Pallavaram, Chennai – 600117, India. Abstract Adverse drug reaction (ADR) is defined by the World Health Organization (WHO) as “any response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function”. The recent epidemiological studies say that the adverse drug reactions (ADRs) are fourth to sixth leading cause of death. Adverse drug reactions (ADRs) are the major reason behind the cause of morbidity and mortality, and also the leading cause of hospital admissions. ADRs negatively affect the patient’s quality of life and confidence in medications, which consequently leads to worse treatment outcomes. Monitoring of ADRs should be an ongoing, continuing and ceaseless process. The most ADRs would subside once the causative agent is discontinued or dose is being reduced; however, many ADRs results in permanent damage to the patients. Monitoring of ADRs is even more important in case of chronic conditions such as hypertension. Hypertension is an asymptomatic disorder and requires long term treatment predisposing to adverse drug reactions. Most of the adverse drug reactions are predictable and preventable. Therefore continuous monitoring and reporting of ADRs can have a positive impact on the medication use, improving the patient’s quality of life and in reducing the incidence of devastating ADRs. The active surveillance of a clinical pharmacist in detecting the Adverse Drug Reactions and giving the awareness regarding the need of monitoring and reporting of adverse drug reactions among healthcare professionals would improve the scenario in under-reported hospitals. Keywords: Adverse Drug Reactions (ADRs), Antihypertensive Drugs, Hypertension, Clinical Pharmacist, ADRs reporting. Volume 27, Issue 3, 2021 14 http://www.gjstx-e.cn/ High Technology Letters ISSN NO : 1006-6748 I. INTRODUCTION Adverse drug reaction (ADR) has been defined by the World Health Organization (WHO) as “any response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function”. The recent epidemiological studies say that the adverse drug reactions (ADRs) are fourth to sixth leading cause of death [1] . Adverse drug reactions are seen in day to day clinical practice. Estimation of the incidence rate of adverse drug reactions is very difficult and highly variable among countries all over the world. Prevalence of adverse drug reactions is 14.7% in United Kingdom and 16.2% in India [2,3] . The incidence of hospital admissions due to adverse drug reactions ranges from 2.4 to 12% while incidence of ADRs during hospital stay ranges from 0.05 to 0.19 % [4,5] . Fatality due to ADRs was found to be 0.3% [6]. Adverse drug reactions (ADRs) are the major reason behind the cause of morbidity and mortality, and also the leading cause of hospital admissions. ADRs negatively affect the patient’s quality of life and confidence in medications, which consequently leads to worse treatment outcomes [7]. Lack of reliable data on the true prevalence and incidence of ADRs is the major limitation in adverse drug reaction research. The incidence rate of adverse drug reactions is captured through voluntary reporting systems. Due to under- reporting the true incidence of adverse drug reaction is not known, which results in lack of information about the number of patients at risk and making assessment of the relative frequencies of different adverse drug reactions are impossible. Singapore stands the highest rate in spontaneous ADR reporting in the world. Even though under-reporting, incomplete information of the data and reporting bias causes inability to calculate the true prevalence of ADRs [8,9]. Monitoring of ADRs should be an ongoing, continuing and ceaseless process. Adverse drug reaction monitoring and reporting is still infancy in India, this must likely to change and expand in future years. As the newer medications are striking the Indian market, the need for ADR monitoring is important more than ever before. Therefore, monitoring of the adverse drug reactions particularly those of serious nature is obligatory. The most ADRs would subside once the causative agent is discontinued or dose is being reduced; however, many ADRs results in permanent damage to the patients. Therefore, it is important to motivate the healthcare providers to know their role and responsibility within the detection, treatment, documentation, and reporting of adverse drug reactions. Since most of the clinical trials exclude the geriatric, pediatric, pregnant women, patients with multiple diseases or metabolic disorder, and those on medication suspected of interactions with the study drug or investigational drug, thus the study population may not be the true representative of the real world where the medications are eventually used. Hence, there is a need to monitor the adverse drug reactions of all the medications on continuous basis. Monitoring of ADRs is even more important in case of chronic conditions such as hypertension. Hypertension is an asymptomatic disorder and requires long term treatment predisposing to adverse drug reactions. A study by Fowad Khurshid et al . carried out to monitor the adverse drug reactions (ADRs) caused by antihypertensive medicines prescribed in a university teaching hospital, New Delhi, India were a total of 21 adverse drug reactions were seen in 192 hypertensive patients. Combination therapy showed higher number of adverse drug reactions (66.7%) when compared to monotherapy (33.3%). Calcium channel blockers were found to be the most frequently associated drugs with the occurence of adverse drug reactions (n = 7), followed by diuretics (n = 5), and β-blockers (n = 4). Among individual medications, amlodipine was found to be associated with maximum number of adverse drug reactions (n = 7), followed by Volume 27, Issue 3, 2021 15 http://www.gjstx-e.cn/ High Technology Letters ISSN NO : 1006-6748 torasemide (n = 3). Pain in abdomen, ankle oedema, sedation, pedal oedema, and back pain were the adverse drug reaction observed with the use of amlodipine. Adverse drug reactions associated with central nervous system were found to be the most frequent (42.8%) followed by musculo-skeletal complaints (23.8%) and gastro-intestinal disorders (14.3%) [10,11]. Adverse drug reactions profile of antihypertensive medications will be useful in selecting the appropriate medicines for hypertension patients, improving patient adherence with the medications by selecting the medicines of fewer adverse drug reactions profile, reducing unnecessary financial burden to the patients due to the unintended effects of the medications. II. ADVERSE DRUG REACTIONS OF BETA- BLOCKERS 2.1. Raynaud’s phenomenon and Peripheral vasoconstriction: β-adrenoceptor blockers-induced Raynaud’s phenomenon (RP) is well known adverse drug reactions caused by beta blockers but its true incidence was not known. Beta-adrenoceptor blocker is the most common cause of secondary RP which was estimated by analysis of the Framingham Heart study data (34.2% of secondary RP). A meta-analysis was conducted in 2012 which includes 13 studies were 1012 patients are involved and this analysis observed a prevalence of 14.7% in patients receiving Beta blockers [12] . Transient ischaemia of the extremities is the characterization of Raynaud’s phenomenon (RP). Its clinical manifestation includes: changes to the fingers associated with pallor (vasospasm and decreased blood flow), cyanosis (deoxygenation of the static venous blood) and rubor (reperfusion), often accompanied by pain. RP is of two types: primary (i.e. idiopathic) and secondary. In both the type abnormality in the cutaneous microcirculation are mainly involved in the pathophysiology of RP. RP is aggravated or induced by several drugs which have peripheral vascular effects causing decreased microvascular perfusion. Due to limited information of this adverse drug reaction drug-induced RP probably goes unrecognized in clinical settings. A network meta-analysis of prospective randomized controlled trials was conducted which showed a prevalence of peripheral vasoconstriction among patients treated with Beta blockers of 7%. 4.6% and 1.7% of patients treated with placebo or active control experienced this adverse drug reaction [13,14,15] . Peripheral vasoconstriction is a known vascular adverse drug reactions of beta blockers. Beta-adrenoceptor blockers are known to induce peripheral vasoconstriction, probably according to their pharmacological properties (e.g. preferential binding to Beta 1‐adrenoreceptors,